NCT01594229 - A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 21, 2012

Primary Completion Date

July 14, 2020

Study Completion Date

July 14, 2020

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

ABT-199

ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.

DRUG

Rituximab

Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.

DRUG

Bendamustine

Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.

Trial Locations (8)

21287

Johns Hopkins University /ID# 67345, Baltimore

30322

Emory University Hospital /ID# 67349, Atlanta

30912

Georgia Regents University /ID# 67342, Augusta

48202

Henry Ford Health System /ID# 67346, Detroit

60426

Ingalls Memorial Hosp /ID# 67344, Harvey

77030

University of Texas MD Anderson Cancer Center /ID# 69222, Houston

90095

University of California, Los Angeles /ID# 67343, Los Angeles

92093

Ucsd /Id# 67350, La Jolla